Why Timing Matters and the Case for Early TIL Therapy

Timing matters when considering tumor-infiltrating lymphocyte (TIL) therapy. Medical oncologist James Smithy, MD, MHS, of Memorial Sloan Kettering Cancer Center explains that TIL is a one-time infusion rather than ongoing cycles, meaning most side effects happen in a predictable 1-month window without the risk of new immune-related side effects showing up over time. He reviews 5-year data from the pivotal phase 2 trial showing that people who are less heavily pretreated and have less disease in their body have higher response rates to TIL therapy. Dr Smithy emphasizes how helpful it can be to introduce TIL as a potential backup plan while someone is still on first-line immunotherapy, so there's time to learn about it before urgent decisions are needed. He and acute care nurse practitioner Mary Montefusco, ACNP, also discuss how to share information at the right pace for different people.